The fundamental difference: inference vs. measurement
Here's what most wearable marketing skips. There are two types of hormone tracking: measurement and inference.
Measurement means you're actually detecting hormone metabolites. Mira and Oova measure estrone-3-glucuronide (E3G), luteinising hormone (LH), and progesterone metabolites (PdG) in urine samples. This shows 99% correlation to blood hormone levels. It's direct.
Inference means the wearable is measuring temperature, heart rate, heart rate variability, and sleep, then running machine learning to guess what's happening hormonally. This is what Oura Ring does. It's educated guessing, but it's not the hormone itself.
Oura's Perimenopause Check-In, launched in 2025, analysed 24 million nights of sleep data from 850K+ women aged 40–60. The data is massive. But the feature detects perimenopause symptoms through patterns in sleep disruption, temperature, and self-reported symptoms — not direct hormone measurement. It's useful for understanding your transition, but it's not telling you your estrogen level.
What each wearable can and cannot do
Oura Ring (Perimenopause Check-In)
Can detect: sleep disruption patterns, body temperature trends, resting heart rate variability. Uses 24M+ data points to signal perimenopause likelihood.
Cannot detect: your actual estrogen or progesterone levels. Cannot predict ovulation reliably. Cannot tell you which perimenopause phase you're in with clinical precision.
Realistic use: if your sleep is fragmented, your resting heart rate elevated, and your temperature spiking at night, Oura will recognise the pattern and suggest perimenopause. It's a useful screening tool, not a diagnostic or hormone-tracking device.
Apple Watch
Can detect: heart rate spikes (often associated with hot flushes), temperature fluctuations, activity and sleep patterns. New cycle-tracking features estimate ovulation via basal body temperature and period prediction.
Cannot detect: specific hormone levels or the full hormonal chaos of perimenopause reliably. Temperature shifts during perimenopause are erratic and don't follow normal cycle patterns, making inference harder.
Realistic use: if you notice your Apple Watch recording elevated heart rates during the day or night sweats, that's useful data to bring to your doctor. The ovulation estimate works better in regular cycles than in perimenopausal unpredictability.
Mira Fertility Tracker (with Menopause Mode)
Can detect: FSH, LH, E3G, and PdG through quantitative urine analysis. 2025 lab study showed results closest to blood hormone values compared to 3 competitors.
Cannot detect: real-time hormone levels (results show what happened in the 24–48 hours before the test).
Realistic use: if you want objective hormone data during perimenopause, this is the most validated non-blood option. Test every few days to track FSH and LH patterns. Helps clarify whether symptoms are perimenopause or something else.
Clair Continuous Wearable (2026 Validation)
Can detect: 130+ biomarkers across cardiovascular, thermoregulatory, autonomic, and electrodermal domains. Validated at 94% accuracy for cycle phase detection and 87% sensitivity for LH surge in a 40-woman, 127-cycle study.
Cannot detect: absolute hormone values. Predicts hormone state from multi-modal sensor data via machine learning.
Realistic use: emerging science. Not yet widely available. Shows promise for perimenopause tracking, but longer-term validation is needed.
No wearable currently available gives you a direct readout of estrogen levels. The closest you get is Mira's urine hormone testing (not a wearable, but quantitative) or Clair's inference-based prediction. For perimenopause, where hormone fluctuations are chaotic, even these have limitations. Most wearables detect patterns of disruption (poor sleep, temperature swings) but not the hormones themselves.
Which wearable is right for perimenopause?
- For objective hormone data: Mira Menopause Mode (quantitative testing, highest lab correlation)
- For symptom pattern tracking: Oura Ring Perimenopause Check-In (best data set, contextualises your personal patterns)
- For basics you already own: Apple Watch (cycle tracking, heart rate, sleep — useful but less perimenopause-specific)
- For emerging validation: Clair (most promising biomarker inference, but still early, limited availability)
The realistic timeline for results
If you start tracking today, expect a learning period of 1–3 months. Wearables need data to establish your baseline. Early perimenopause looks different from late perimenopause. Your personal patterns matter more than population data.
Use wearable data alongside symptom tracking (a simple spreadsheet works: date, sleep quality, mood, hot flashes, period status). Bring both to your doctor. The combination of wearable data and symptom observation is more useful than either alone.
What to tell your doctor about your wearable data
Bring actual data, not just impressions. Show your doctor sleep patterns, temperature charts, or Mira hormone test results. Say "My Oura detected two weeks of poor sleep" or "My Mira shows FSH rising." This gives your doctor actionable information. Avoid "my app says I'm in perimenopause" — that's the doctor's job. But "here's my sleep disruption pattern" is useful context.
References
- Mira Fertility 2026 Women's Health Trends Report. Based on 105 healthcare professionals, 2,000 women, global research. Full report
- Case Reports from Women Using a Quantitative Hormone Monitor to Track Perimenopause Transition. PMC. 2024;10608103. PMC10608103
- Mira Ultra 4: 7x Better Accuracy in Hormone Tracking. Validation study comparing LH, FSH, E3G, PdG to lab values. 2025. Tech review
- Clair Continuous Hormone Monitoring Wearable: Validation on 40+ women, 127 cycles. 94.1% cycle phase accuracy, 87% LH surge sensitivity. Clair research
- Oura Ring Perimenopause Check-In: Analysis of 24 million nights from 850K+ women aged 40–60. Oura blog